Discount Drug Program Passes OIG Scrutiny

by Baker Ober Health Law
Contact

On July 28th, 2014, the Department of Health and Human Services, Office of Inspector General (OIG) released favorable advisory opinion 14-05, concluding that a pharmaceutical manufacturer’s direct-to-patient discounted, cash product sales program did not violate the federal antikickback statute (AKS) or the civil monetary prohibition on inducements to beneficiaries (CMP).

Factual Overview

A pharmaceutical manufacturer (Manufacturer) sought approval from the OIG to sell one of its brand name prescription drugs (Discount Drug) directly to patients with a valid prescription, at a discounted price, irrespective of the patient’s insurer. While eligible for Part D coverage, the Discount Drug is not covered by a large majority of Part D plans (PDPs) due to the availability of generic equivalents. Moreover, where covered, the Discount Drug is placed on PDP non-formulary tiers with restrictions on coverage and reimbursement.

Enrollment

To enroll, participants must provide a valid prescription for the Discount Drug, identify their insurance (if any), and agree to allow the Manufacture to share information with third parties, as needed, to facilitate the administration of the Discount Drug Program.

Those patients with Medicare Part D insurance must further agree to (1) allow the Manufacturer to send a written notice to their PDP regarding their participation; (2) obtain the product only through the Discount Drug program for the applicable Part D coverage year; (3) not submit any claim for reimbursement for the Discount Drug to any third-party payor; and (4) not include the amounts paid for the Discount Drug in any submission for true out-of-pocket (TROOP) expenses calculations under the PDP.

At the end of each Part D coverage year, the Manufacturer automatically re-enrolls program participants for the next coverage year, unless a participant affirmatively opts out. In the event the Discount Drug Program terminated or participants affirmatively sought to opt out of it, the Manufacturer certified that participants would face no clinical barriers to switching from the product to the product’s generic equivalents.

Once enrolled, communications between all participants and the Manufacturer are limited to the Discount Drug Program and its related diseases states. Communications do not extend to other products offered by the Manufacturer.

Online Retail Pharmacy

All participants must purchase the Discount Drug from the Manufacturer’s dispensing agent, an online retail pharmacy vendor (Pharmacy). The price of the Discount Drug is at a fixed cash price set by the Manufacturer (which is “substantially lower” than the Manufacturer’s whole sale acquisition cost), and is paid by all participants to the Pharmacy. The Pharmacy then collects participant payments and sends the full amount to the Manufacturer.

Communications between participants, participants’ physicians, and the Pharmacy are, like that between participants and the Manufacturer, limited. Communications pertain only to order notifications, shipment notifications, and email reminders.

Service Arrangement Agreement

In exchange for the services provided by the Pharmacy, the Manufacturer pays the Pharmacy both a flat monthly fee for operational expenses, and a flat per-transaction fee for each Discount Drug ordered. The Manufacturer also pays a flat, one-time fee for the Pharmacy’s start-up costs related to its Discount Drug services. The Pharmacy is prohibited from filing any claim for payment under any federal health care program, and instead must process all participants as cash-paying customers.

The Manufacturer certified that its fee arrangement with the Pharmacy is the product of an arms-length negotiation, that all fees reflect fair market value for the services provided, and that the arrangement does not take into account the volume or value of referrals or other business generated between the parties.

In addition to the above payment terms, the service arrangement between the Manufacturer and the Pharmacy requires the Pharmacy to: (1) segregate all Discount Drugs supplied by the Manufacturer to the Pharmacy for sale; (2) comply with all applicable laws; (3) refrain from offering any inducement to a health care provider to prescribe, or switch participants to, drugs sold by the Manufacturer; and (4) allow the Manufacturer to audit the Pharmacy to confirm compliance with the terms of the agreement.

OIG’s Analysis

Civil Monetary Penalties Law

In the Drug Discount Program, participants receive remuneration from the Pharmacy (on behalf of the Manufacturer) via a discount on the price of the Discount Drug. Notwithstanding the discount, and the CMP risk that it presents, the OIG concluded it was unlikely to induce participants to select the Pharmacy to supply other products payable by Medicare or Medicaid because: (1) participants are not required to purchase any items other than the Discount Drug from the Pharmacy; and (2) the Manufacturer certified that it would permit only limited, well defined communications with participants to ensure that the discount does not serve as a vehicle to market other federally reimbursable products that it manufactures.

More specifically, the OIG highlighted the Manufacturer’s participant communication policies, which strictly limit Manufacturer and Pharmacy communications with participants to matters concerning or related to the Discount Drug Program. The marketing of other products is expressly prohibited.

Federal Antikickback Statute

Despite finding both the personal service arrangement safe harbor and discount safe harbor inapplicable (due to the per-transaction fee structure and the fact that no claim for payment would be filed with a federal health care program, respectively), the OIG nonetheless determined the arrangement posed a minimal risk under the AKS.

In its analysis, the OIG first highlighted the remuneration provided to participants via a discount on the price of the Discount Drug. However, because the Manufacturer certified that (1) it (and the Pharmacy) would not use the Discount Drug Program as a means to market other federally reimbursable products; (2) in the event the Discount Drug Program terminated, most PDP plans would not cover the Discount Drug; and (3) that no clinical barriers prevent participants from switching to the Discount Drug’s generic equivalent, the OIG determined that it was unlikely the purpose of the Discount Drug program was to induce participants to later purchase the Discount Drug with the assistance of federal health care programs.

Secondly, the OIG noted that the remuneration provided from the Manufacturer to the Pharmacy may induce the Pharmacy to arrange for or recommend the purchase of the Manufacturer’s other products payable by a federal health care program. However, the OIG’s concerns were again addressed by the Drug Discount Program safeguards: (1) all fees in the arrangement between the Pharmacy and the Manufacturer were consistent with fair-market value in an arms-length transaction; (2) all per-fee transactions took into account only those services necessary to dispense the Discount Drug; and (3) both the Manufacturer and the Pharmacy agreed not to offer, promote, or market any of their products or services other than the Discount Drug and the services required to dispense the Discount Drug, in contrast to other problematic carve-out arrangements.

OIG Caveats

Upon concluding that the Discount Drug Program did not run afoul of the AKS or CMP, the OIG noted several unique aspects of the arrangement at issue, stating that it “may have reached a different conclusion” in the event the Discount Drug had no generic equivalents, was covered by more plan formularies, and/or was more generously covered by some PDP plan formularies.

Ober|Kaler Comments

Interestingly, the OIG was unwilling to rely solely on the fact that the arrangement operated outside of the federal health care programs, with no claims filed by the participants or the Pharmacy with any federal health care program. The OIG considered whether the arrangement might have other indirect effects on federal health care programs. Based on a number of factors, the OIG concluded that the arrangement contained sufficient safeguards. Given the particular nature of the arrangement, as highlighted by the OIG’s caveats, it seems unlikely that this advisory opinion will have broad applicability.

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Baker Ober Health Law | Attorney Advertising

Written by:

Baker Ober Health Law
Contact
more
less

Baker Ober Health Law on:

Readers' Choice 2017
Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
Sign up using*

Already signed up? Log in here

*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Privacy Policy (Updated: October 8, 2015):
hide

JD Supra provides users with access to its legal industry publishing services (the "Service") through its website (the "Website") as well as through other sources. Our policies with regard to data collection and use of personal information of users of the Service, regardless of the manner in which users access the Service, and visitors to the Website are set forth in this statement ("Policy"). By using the Service, you signify your acceptance of this Policy.

Information Collection and Use by JD Supra

JD Supra collects users' names, companies, titles, e-mail address and industry. JD Supra also tracks the pages that users visit, logs IP addresses and aggregates non-personally identifiable user data and browser type. This data is gathered using cookies and other technologies.

The information and data collected is used to authenticate users and to send notifications relating to the Service, including email alerts to which users have subscribed; to manage the Service and Website, to improve the Service and to customize the user's experience. This information is also provided to the authors of the content to give them insight into their readership and help them to improve their content, so that it is most useful for our users.

JD Supra does not sell, rent or otherwise provide your details to third parties, other than to the authors of the content on JD Supra.

If you prefer not to enable cookies, you may change your browser settings to disable cookies; however, please note that rejecting cookies while visiting the Website may result in certain parts of the Website not operating correctly or as efficiently as if cookies were allowed.

Email Choice/Opt-out

Users who opt in to receive emails may choose to no longer receive e-mail updates and newsletters by selecting the "opt-out of future email" option in the email they receive from JD Supra or in their JD Supra account management screen.

Security

JD Supra takes reasonable precautions to insure that user information is kept private. We restrict access to user information to those individuals who reasonably need access to perform their job functions, such as our third party email service, customer service personnel and technical staff. However, please note that no method of transmitting or storing data is completely secure and we cannot guarantee the security of user information. Unauthorized entry or use, hardware or software failure, and other factors may compromise the security of user information at any time.

If you have reason to believe that your interaction with us is no longer secure, you must immediately notify us of the problem by contacting us at info@jdsupra.com. In the unlikely event that we believe that the security of your user information in our possession or control may have been compromised, we may seek to notify you of that development and, if so, will endeavor to do so as promptly as practicable under the circumstances.

Sharing and Disclosure of Information JD Supra Collects

Except as otherwise described in this privacy statement, JD Supra will not disclose personal information to any third party unless we believe that disclosure is necessary to: (1) comply with applicable laws; (2) respond to governmental inquiries or requests; (3) comply with valid legal process; (4) protect the rights, privacy, safety or property of JD Supra, users of the Service, Website visitors or the public; (5) permit us to pursue available remedies or limit the damages that we may sustain; and (6) enforce our Terms & Conditions of Use.

In the event there is a change in the corporate structure of JD Supra such as, but not limited to, merger, consolidation, sale, liquidation or transfer of substantial assets, JD Supra may, in its sole discretion, transfer, sell or assign information collected on and through the Service to one or more affiliated or unaffiliated third parties.

Links to Other Websites

This Website and the Service may contain links to other websites. The operator of such other websites may collect information about you, including through cookies or other technologies. If you are using the Service through the Website and link to another site, you will leave the Website and this Policy will not apply to your use of and activity on those other sites. We encourage you to read the legal notices posted on those sites, including their privacy policies. We shall have no responsibility or liability for your visitation to, and the data collection and use practices of, such other sites. This Policy applies solely to the information collected in connection with your use of this Website and does not apply to any practices conducted offline or in connection with any other websites.

Changes in Our Privacy Policy

We reserve the right to change this Policy at any time. Please refer to the date at the top of this page to determine when this Policy was last revised. Any changes to our privacy policy will become effective upon posting of the revised policy on the Website. By continuing to use the Service or Website following such changes, you will be deemed to have agreed to such changes. If you do not agree with the terms of this Policy, as it may be amended from time to time, in whole or part, please do not continue using the Service or the Website.

Contacting JD Supra

If you have any questions about this privacy statement, the practices of this site, your dealings with this Web site, or if you would like to change any of the information you have provided to us, please contact us at: info@jdsupra.com.

- hide
*With LinkedIn, you don't need to create a separate login to manage your free JD Supra account, and we can make suggestions based on your needs and interests. We will not post anything on LinkedIn in your name. Or, sign up using your email address.
Feedback? Tell us what you think of the new jdsupra.com!